Basophil biomarkers as useful predictors for sublingual immunotherapy in allergic rhinitis

Mechanisms of allergen-specific immunotherapy

“…In both food and aeroallergen IT, a decrease in basophil responsiveness has been observed. 60 A recent study by Caruso et al 61 suggested the use of the allergen sensitivity threshold (CD-Sens) by basophil activation tests to predict clinical efficacy of and monitor the immune responses to AIT. A significant decrease of allergic symptom severity in allergic rhinitis patients after 12 months of SLIT and increased tolerability of basophils to the pollen allergen Parietaria (CD-Sens) was observed, which was measured by expression of the basophil activation surface markers CD63 and CD203c on stimulated basophils.…”

“…However, only CD203c appears to be correlated to clinical symptoms. 61 Another study in patients with seasonal allergic rhinitis receiving SCIT or SLIT 62 explored the potential of quantifying intracellular histamine-binding fluorochrome-labeled diamine oxidase, as a surrogate for histamine release, in whole-blood basophils together with measuring the surface expression of CD63, CD203c, and CD107a. Reduced basophil responsiveness and histamine release after both SCIT and SLIT was demonstrated and was correlated with lower allergic rhinitis symptom scores.…”

Diverse Mechanisms of Allergen Specific Immunotherapy

“…After 12 months of SLIT, the patients showed reduced severity of allergic symptoms and increased tolerability of basophils to the Parietaria with the guidance of CD-Sens through both CD63 and CD203c. Nonetheless, corresponding with clinical symptoms, only CD203c showed a correlation in patients [80].…”

Mechanisms of allergen-specific immunotherapy for allergic rhinitis and food allergies

“…In the study by Shamji et al [170], reduced basophil responsiveness and histamine release, through the quantification of intracellular histamine-binding fluorochrome-labeled diamine oxidase and measurement of CD63, CD203c and CD107a cell surface expression, were reported in whole-blood basophil from AR patients after both SCIT and SLIT and the result was correlated to lower symptom scores. Increased tolerability of basophils to Parietaria allergen (CD-Sens measured by CD63 and CD203c) and a significantly reduced symptom severity were observed in AR patients treated with SLIT [171]. Further, significantly decreased basophil activation was also observed after peanut OIT (Peanut oral immunotherapy study: safety, efficacy and discovery -POISED study) and this is correlated to higher sIgG4/ sIgE ratio and the study suggested that patients with low basophil responsiveness were more likely to achieve treatment success to peanut OIT [172].…”